The Utility of the Platelet–Lymphocyte Ratio for Predicting No Reflow in Patients With ST-Segment Elevation Myocardial Infarction. (April 2015)

• Record Type: Journal Article
• Authors: Yildiz, Abdulkadir; Yuksel, Murat; Oylumlu, Mustafa; Polat, Nihat; Akyuz, Abdurrahman; Acet, Halit; Aydin, Mesut; Ülgen, Mehmet Siddik
• Is Part Of: Clinical and applied thrombosis/hemostasis. Volume 21:Number 3(2015:Apr.)
• Page Start: 223
• Page End: 228
• Publication Date: 2015-04
• Subjects: primary percutaneous coronary intervention -- acute ST-segment elevation myocardial infarction -- platelet to lymphocyte ratio -- no reflow; Hemostasis -- Periodicals; Thrombosis -- Periodicals; 616.13
• DOI: 10.1177/1076029613519851
• Languages: English
• ISSNs: 1076-0296

Abstract

The aim of the study was to evaluate the utility of the preprocedural platelet–lymphocyte ratio (PLR) for predicting no reflow in patients undergoing primary percutaneous intervention (PCI) for the treatment of ST-segment elevation myocardial infarction. The thrombolysis in myocardial infarction (TIMI) flow grades of 287 patients treated with primary PCI were assessed retrospectively. Patients were divided into 3 tertiles based upon preprocedural PLR. Pre- and postprocedural TIMI flow grades were evaluated. No reflow developed in 6, 14, and 43 patients in the lower, middle, and higher tertiles, respectively ( P < .001). After multivariate analysis, PLR remained a significant predictor of no reflow together with neutrophil–lymphocyte ratio (NLR). A cutoff value of 160 for PLR and 5.9 for NLR predicted no reflow with sensitivities and specificities of 75% and 71% and 74% and 70%, respectively. In conclusion, high preprocedural PLR and NLR levels are significant and independent predictors of no reflow in patients undergoing primary PCI.